Tumor acidosis

Upregulated glucose metabolism, as a consequence of increased lactate and H+ extrusion from anaerobic glycolysis, even in presence of sufficient oxygen ("Warburg effect"), associated with acidification of the extracellular space (pHe 6.2-6.8) is one of the major features of cancer. However, tumor cells are well adapted to acidic microenvironments, since they rely on proton exchangers and transports, which exports protons to the microenvironment. Several pH regulators are therefore involved in preserving such pH homeostasis, including ATPases, Na+/H+ exchangers (NHEs), monocarboxylate transporters (MCTs) carbonic anhydrases (CAs) and anion exchangers (AEs). Moreover, tumor acidification (or tumor acidosis) has been associated with key features of cancer aggressiveness, including invasion, increase angiogenesis and resistance to therapy and evasion from the immune system.

It is becoming increasingly evident that extracellular acidosis could be targeted to block tumor proliferation using for example proton pump inhibitors, which are first responsible of H+ exporting mechanism. Even more important is that changes in the level of acidosis can be used as a marker of therapeutic response. As a consequence, novel imaging approaches are urgently needed for non-invasively assessing the efficacy of novel anticancer therapies.

To date, imaging-based methods are commonly used in clinical settings to assess glucose metabolism (using FDG-PET), providing a formidable tool for evaluating treatment response. However, significant shortcomings of FDG-PET approach are related to radiation exposure (limiting repeated exams in a single individual) and to radioactive compound 18F production (local cyclotron owing to the short half-life) which cannot be found in every hospital. Conversely, an effective imaging method that allows to quantify extracellular tumor pH and to assess pHe related changes following therapeutic treatment is still missing.
Other imaging-based approaches, namely magnetic resonance spectroscopy (MRS) and imaging (MRI) have been investigated. However, none of them has shown feasibility to provide pHe maps with sufficient spatial resolution and pH accuracy and to be easily translated into clinical settings.

Recently, MRI-CEST (Chemical Exchange Saturation Transfer) based methods for measuring pHe with improved accuracy, concentration-independence and spatial resolution have been proposed and investigated in preclinical tumor models (Longo D et al., Cancer Research 2016, 76, 6463).
Consequently, MRI-CEST pH imaging can play a role as an alternative to FDG-PET to characterize tumor metabolism and for assessing treatment response.

Within our center we have developed several CEST-based pH sensors for the non-invasive assessment of tumor pH. Among them, clinical approved radiographic contrast agents such as Iopamidol, iobitridol and iodixanol have been exploited for measuring tumor pHe in murine tumor models. Moreover, we have investigated lanthanide PARACEST complexes (Yb-HPDO3A) to measure extracellular pH.

We are interested to assess:

  • the relationship between tumor acidosis and glucose uptake,
  • the role of tumor acidosis in cancer progression and invasion,
  • tumor pHe imaging as a biomarker of treatment response to novel anticancer therapies.

Group Leaders:

Dario Longo Daniela Delli Castelli Giuseppe Ferrauto